Cosentyx (secukinumab) — United Healthcare
active psoriatic arthritis
Initial criteria
- Diagnosis of active psoriatic arthritis
- Patient is not receiving Cosentyx in combination with another targeted immunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Otezla (apremilast), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Taltz (ixekizumab), Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib)]
Reauthorization criteria
- Documentation of positive clinical response to Cosentyx therapy
- Patient is not receiving Cosentyx in combination with another targeted immunomodulator [same list as above]
Approval duration
12 months